BRIEF-Alkermes Plc says initiates phase 3 gastrointestinal tolerability study of ALKS 8700

* Alkermes Plc says initiates phase 3 gastrointestinal tolerability study of ALKS 8700 for treatment of multiple sclerosis
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.